drugset / Trial / NCT04316377

Norwegian Coronavirus Disease 2019 Study

NCT04316377

Phase 4 Unknown 53 enrolled University Hospital, Akershus
RandomizedParallel-groupOpen-labelTreatment

Summary

In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.

Timeline

Start
2020-03-25
Primary completion
2020-05-25
Completion
2025-03-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxychloroquine Small molecule 400 mg

Indications